Why is Abbott Laboratories stock up 2% today?

Traders Union
All News
Stocks
Abbott laboratories rises 2.06% today

Highlights

Large institutional investors acquired substantial new positions in Abbott Laboratories stock during the second quarter, including Haverford Trust Co and Peak Asset Management LLC.
Abbott Laboratories reported quarterly earnings of $1.31 per share on $12.59 billion revenue, surpassing consensus estimates.
Shares of Abbott Laboratories remain in a medium- to long-term supportive structure with an expected five-day trading range of $107.75 to $113.6, while mixed momentum signals indicate potential for both upward and downward moves.

Institutional buying intensifies as dividend and earnings beat support sentiment

Major institutional investors purchased sizable new positions in Abbott Laboratories during the second quarter, including Haverford Trust Co, Peak Asset Management LLC, and Osmosis Investment Management UK Ltd. The company recently declared a quarterly dividend of $0.63 per share, paid on August 17, 2025, resulting in an annualized yield of 2.3%. Abbott Laboratories reported earnings of $1.31 per share for the latest quarter on revenue of $12.59 billion, exceeding consensus estimates.

Anton Kharitonov, expert at Traders Union, notes that Abbott Laboratories' recent uptick is underpinned by strong institutional inflows and above-consensus earnings, but he remains wary. He finds the stock’s inability to reclaim its 20-day moving average troubling, with clear resistance near today's highs and a structurally fragile technical picture. The dividend announcement offers only modest support to sentiment and may not offset underlying bearish trends. While medium- and long-term supports hold, the analyst emphasizes the downside risk if $110.16 fails to sustain. "A corrective pullback remains likely unless we see a clear reversal of technical weakness and broader conviction from buyers," Kharitonov cautions.

Viktoras Karapetjanc, expert at Traders Union, highlights robust institutional buying and steady dividend payments as key drivers for further upside in Abbott Laboratories. He views the earnings beat and high-profile investor activity as strong confirmation of the company’s resilience and attractiveness. The analyst believes the current trading range offers an opportunity for investors to position ahead of potential acceleration. "With institutional flows and fundamentals aligning, the bullish structure remains intact and sets the stage for further growth toward the upper volatility band," Karapetjanc states.

Jainam Mehta, market strategist, observes that Abbott Laboratories is consolidating between key technical levels with mixed momentum. Mehta notes the near-term resistance at $111.43 and sees tactical trading opportunities around volatility bands. He suggests a contrarian trade may emerge if sentiment diverges and the stock fails to break out. "I see merit in waiting for a decisive move above resistance or a confirmed pullback to $107.75 before taking positions here," Mehta advises.

Short-term resistance persists as long-term momentum stays subdued

Abbott Laboratories is currently trading below its 20-day moving average ($111.59), but remains above both the 50-day ($103.3) and 200-day ($106.62) moving averages. While this short-term setup suggests resistance is likely as the stock lags its short-term average, support persists in the medium- to long-term structure. The nearest support is provided by the Ichimoku Kijun at $110.16, with today's high at $111.43 acting as immediate resistance. The longer-term trend context is still bearish due to the 50-day average staying under the 200-day.

Earlier, analysts noted that Abbott Laboratories maintained a bullish long-term structure despite near-term consolidation risks and mixed short-term signals. The current setup reinforces this perspective, with price action indicating an ongoing consolidation phase and making $111.43 the pivotal level to monitor for a potential breakout or renewed downside toward $107.75.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.